AKTS
AKTS
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
6
$114.31M
Insider Sales
5
$3.23M
Total Volume
$117.54M
11 transactions
Net Activity
+$111.08M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 97% of total transaction value.
- •Cluster buying: 6 unique insiders purchased shares, showing strong alignment.
- •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Ecor1 Capital, LLC
Dir
$40.00M total
Mpm Bioventures 2018, L.P.
10%
$20.03M total
Gadicke Ansbert
10%
$20.03M total
Vida Ventures Ii, LLC
10%
$15.03M total
Kim Helen Susan
Dir, 10%
$15.03M total
Quick Actions
AKTS has an insider buy conviction of 97%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at AKTS (AKTS) engaged in a total of 11 transactions reported via SEC Form 4 filings. Among these, 6 were open-market purchases and 5 were sales. The total volume of insider trading reached $117.54M.
The net insider activity for AKTS shows a net buying bias of $111.08M. This activity represents a 97% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Ecor1 Capital, LLC (Dir), who traded 2.22M shares valued at $40.00M on Jan 12, 2026.
Aktis Oncology (NASDAQ:AKTS) Stock: Research Spending and a Large Cash Balance Define the Quarter
Paul L. Feldman of Aktis Oncology (AKTS) exercises options on 55,035 shares at $1.9022 per share.
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound
Aktis is a Strong Buy at Raymond James on therapeutic platform
Aktis Oncology (NASDAQ:AKTS) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages
Aktis Oncology (AKTS) Stock Analysis Report | Ratings, Financials & Performance
FAQs About AKTS Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for AKTS.